Double maintains 1 strategies that include IOVA - Iovance Biotherapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SPYT | -0.23% | $97.98M | 0.94% |
TOTL | -0.36% | $3.41B | 0.55% |
IBTF | 0.46% | $2.25B | 0.07% |
VRIG | 0.52% | $1.24B | 0.3% |
WEAT | 0.60% | $124.48M | 0.28% |
MINT | 1.22% | $12.28B | 0.35% |
ULST | 1.35% | $558.13M | 0.2% |
MSOS | 1.43% | $491.08M | 0.83% |
EQLS | -1.47% | $7.75M | 1% |
KCCA | 1.56% | $103.15M | 0.87% |
BILS | -1.60% | $3.37B | 0.1356% |
SHV | 1.65% | $19.18B | 0.15% |
CCOR | -1.71% | $71.42M | 1.18% |
FXY | 1.77% | $400.29M | 0.4% |
XONE | 1.85% | $571.03M | 0.03% |
CORN | -1.91% | $66.02M | 0.2% |
SOYB | 1.95% | $28.05M | 0.22% |
CLOI | 1.99% | $873.72M | 0.4% |
BSMR | 2.01% | $219.86M | 0.18% |
BILZ | 2.03% | $737.51M | 0.14% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -30.46% | $272.15M | 1.43% |
VIXY | -26.71% | $195.31M | 0.85% |
USDU | -19.87% | $294.70M | 0.5% |
TAIL | -19.08% | $65.47M | 0.59% |
UUP | -17.81% | $402.74M | 0.77% |
CTA | -17.49% | $641.27M | 0.76% |
KMLM | -12.84% | $323.07M | 0.9% |
XHLF | -6.07% | $1.07B | 0.03% |
TFLO | -5.16% | $6.49B | 0.15% |
IBMN | -4.77% | $473.89M | 0.18% |
BIL | -4.44% | $37.18B | 0.1356% |
IBD | -4.11% | $337.91M | 0.44% |
AGZD | -3.86% | $137.11M | 0.23% |
CLOA | -3.23% | $689.39M | 0.2% |
TBLL | -3.07% | $2.04B | 0.08% |
SGOV | -2.42% | $33.02B | 0.09% |
CORN | -1.91% | $66.02M | 0.2% |
CCOR | -1.71% | $71.42M | 1.18% |
BILS | -1.60% | $3.37B | 0.1356% |
EQLS | -1.47% | $7.75M | 1% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VTYX | 47.95% | $126.57M | -24.15% | 0.00% |
AWI | 47.65% | $6.68B | +46.40% | 0.75% |
THRM | 45.92% | $1.15B | -23.17% | 0.00% |
CRSP | 45.41% | $3.47B | -41.00% | 0.00% |
NEO | 43.46% | $1.73B | -6.97% | 0.00% |
DIOD | 42.53% | $2.64B | -17.05% | 0.00% |
AKAM | 39.89% | $14.96B | -21.43% | 0.00% |
IHG | 39.67% | $21.54B | +39.87% | 1.15% |
TNL | 39.35% | $3.94B | +42.53% | 3.48% |
ALDX | 38.77% | $357.30M | +85.76% | 0.00% |
FOR | 38.56% | $1.18B | -26.44% | 0.00% |
BARK | 37.47% | $318.34M | +75.96% | 0.00% |
EBS | 37.43% | $566.77M | +522.62% | 0.00% |
PSMT | 37.33% | $2.84B | +19.94% | 1.25% |
TOL | 36.94% | $13.28B | +32.61% | 0.70% |
KN | 36.66% | $1.63B | +16.66% | 0.00% |
BCS | 36.61% | $54.98B | +107.76% | 2.77% |
DFS | 36.44% | $50.88B | +86.26% | 1.38% |
AAMI | 36.15% | $940.41M | +16.77% | 0.16% |
HST | 35.87% | $11.67B | -14.15% | 5.38% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HUSA | -15.91% | $20.71M | -8.33% | 0.00% |
UEIC | -11.01% | $131.58M | +17.72% | 0.00% |
PANW | -10.46% | $122.95B | +2.10% | 0.00% |
MNOV | -10.36% | $94.08M | +37.01% | 0.00% |
PRPO | -10.16% | $10.23M | +6.48% | 0.00% |
LITB | -9.56% | $19.12M | -83.01% | 0.00% |
BTCT | -9.34% | $29.35M | +56.15% | 0.00% |
DOGZ | -9.22% | $452.32M | +973.38% | 0.00% |
WLKP | -8.91% | $877.44M | +13.49% | 5.83% |
MCK | -7.64% | $76.13B | +21.35% | 0.45% |
PCRX | -7.16% | $1.21B | -5.20% | 0.00% |
CHD | -6.25% | $25.82B | +5.46% | 1.08% |
BEST | -6.21% | $32.36M | +24.54% | 0.00% |
TCTM | -6.00% | $4.07M | -52.00% | 0.00% |
STG | -5.68% | $34.92M | -22.58% | 0.00% |
SYPR | -5.63% | $51.80M | +18.42% | 0.00% |
MANU | -5.38% | $2.72B | -26.04% | 0.00% |
TH | -5.28% | $879.59M | -4.20% | 0.00% |
FTNT | -5.13% | $80.26B | +54.34% | 0.00% |
FMS | -5.11% | $14.26B | +23.29% | 2.63% |
Current Value
$5.861 Year Return
Current Value
$5.861 Year Return
Finnhub
SAN CARLOS - Iovance Biotherapeutics, Inc. , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with...
Finnhub
SAN CARLOS, Calif., Jan. 17, 2025 -- Iovance Biotherapeutics, Inc. , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...
Finnhub
Ownership Submission FORM 4 Check this box if no longer...
SeekingAlpha
The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.
Yahoo
Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run. Iovance Biotherapeutics has a market cap of $2.3 billion.
Yahoo
Over the last 7 days, the United States market has experienced a 2.8% drop, yet it remains up by 24% over the past year with earnings forecasted to grow by 15% annually. In this context of fluctuating performance and promising growth prospects, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an evolving technological landscape.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BROS | 0.08% | $7.71B | +156.73% | 0.00% |
NUS | 0.13% | $323.12M | -63.52% | 3.76% |
SRRK | 0.14% | $3.81B | +159.20% | 0.00% |
CYCN | 0.16% | $11.52M | +7.87% | 0.00% |
CYH | 0.16% | $468.25M | -9.65% | 0.00% |
BNED | -0.20% | $335.37M | -86.04% | 0.00% |
NVAX | -0.22% | $1.32B | +118.21% | 0.00% |
ZCMD | 0.22% | $36.69M | -63.58% | 0.00% |
HSBC | -0.22% | $189.23B | +38.20% | 5.72% |
IMRN | -0.24% | $11.73M | +13.56% | 0.00% |
MED | 0.26% | $169.43M | -71.67% | 0.00% |
AJG | -0.30% | $79.93B | +35.00% | 0.75% |
XBIO | 0.34% | $6.31M | +9.55% | 0.00% |
DHT | 0.35% | $1.86B | +4.73% | 8.65% |
CL | 0.38% | $70.00B | +1.69% | 2.33% |
MITK | -0.38% | $469.50M | -16.63% | 0.00% |
FRO | -0.39% | $3.99B | -18.75% | 10.81% |
SMMT | 0.41% | $15.24B | +394.50% | 0.00% |
ITCI | 0.41% | $13.51B | +77.54% | 0.00% |
SCKT | -0.41% | $10.80M | +27.47% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 51.21% | $51.17M | 0.69% |
XBI | 47.95% | $6.19B | 0.35% |
GNOM | 44.13% | $71.39M | 0.5% |
IBB | 43.23% | $6.68B | 0.45% |
IWO | 42.01% | $12.87B | 0.24% |
VTWO | 41.96% | $11.91B | 0.1% |
IWM | 41.94% | $74.54B | 0.19% |
SCHA | 41.61% | $18.95B | 0.04% |
IBUY | 41.56% | $188.93M | 0.65% |
XDTE | 41.56% | $390.23M | 0.95% |
PTH | 41.05% | $130.98M | 0.6% |
SMMD | 41.01% | $1.42B | 0.15% |
KAPR | 40.85% | $164.93M | 0.79% |
IWC | 40.82% | $977.29M | 0.6% |
ESML | 40.78% | $1.95B | 0.17% |
IJT | 40.77% | $6.75B | 0.18% |
KJAN | 40.73% | $355.76M | 0.79% |
PRFZ | 40.50% | $2.67B | 0.39% |
NUSC | 40.36% | $1.28B | 0.31% |
DFAS | 40.33% | $10.07B | 0.26% |